Merck & Co. Accelerates Development of All-Oral HCV Triple-Drug Regimen with Idenix Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 2 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2048 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to add a much-needed nucleotide analogue to its pipeline of drug candidates for chronic hepatitis C virus (HCV) infection, Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS